Linagliptin Viatris (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, leading to higher endogenous incretin levels. The increased incretins stimulate glucose‑dependent insulin secretion and suppress glucagon release, thereby lowering blood glucose without causing significant hypoglycaemia when used alone.

The dosage of linagliptin is determined by the prescribing healthcare professional based on the individual patient's clinical condition, renal and hepatic function, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule, which is typically once daily, but the exact regimen should follow the physician’s order and local prescribing information.

Safety data for linagliptin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Consequently, it is generally recommended to avoid using linagliptin during pregnancy and while breastfeeding unless the potential benefit justifies the potential risk and it is prescribed by a qualified healthcare provider.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors, but it is distinguished by its non‑renal elimination, meaning dose adjustment is not required in patients with renal impairment. Its pharmacokinetic profile allows once‑daily dosing and may provide a convenient option for patients who have reduced kidney function compared with agents that require renal dose modifications.

Linagliptin tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original blister pack or container, protect it from moisture, heat and direct sunlight. Do not store in a refrigerator or freezer, and keep out of reach of children.

Linagliptin is taken orally, usually once a day, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and should not split, crush, or chew the tablet unless specifically instructed to do so.

Serious adverse events associated with linagliptin include pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and rare cases of liver injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, signs of an allergic reaction (e.g., swelling, rash, difficulty breathing), or unexplained jaundice.

Linagliptin should be avoided in patients with a known hypersensitivity to linagliptin or any of the tablet’s excipients. It is also contraindicated in individuals with a history of severe pancreatitis. Caution is advised for patients with moderate to severe liver disease, and the drug should not be used during pregnancy or lactation unless clearly justified by a healthcare professional.